

## List of drugs that may have potential CYP1A2 interactions

### CYP1A2 Substrates

<b>Acenocoumarol</b> Aminophylline Betaxolol Caffeine Clomipramine Clozapine Cyclobenzaprine Dacarbazine Doxepin	<b>Duloxetine</b> Estradiol Estrogens, conjugated (synthetic) Estrogens, conjugated (equine) Estrogens, conjugated (esterified) Estrone	Estropipate Flutamide Fluvoxamine Guanabenz Mexiletine Mirtazapine Pimozide Propranolol Riluzole	Ropinirole Tacrine Theophylline Thiothixene Trifluoroperazine
--	--	--	---

### CYP 1A2 Inhibitors

Albendazole Alosetron Amiodarone Amitriptyline Amlodipine Anastrozole Atazanavir Bortezomib Bromocriptine Buprenorphine Caffeine Cimetidine Ciprofloxacin Citalopram Clarithromycin Clotrimazole Clozapine Delavirdine Dexmedetomidine Diclofenac Disulfiram Drospirenone <i>Echinacea</i> (1) Enoxacin Entacapone	Erythromycin Estradiol Estrogens, conjugated (synthetic) Estrogens, conjugated (equine) Ethinyl estradiol Fluconazole Fluoxetine Fluphenazine Flutamide Fluvastatin Fluvoxamine Gemfibrozil Ginseng (2) Imipramine Interferon- $\alpha$ 2a Interferon- $\alpha$ 2b Interferon- $\gamma$ 1b Isoniazid Ketoconazole Lidocaine Lomefloxacin Losartan Mestranol	Methimazole Methoxsalen Mexiletine Miconazole Mirtazapine <b>Moclobemide</b> Modafinil Nalidixic acid Nefazodone Nelfinavir Nevirapine Nifedipine Nisoldipine Norfloxacin Ofloxacin Olanzapine Omeprazole Ondansetron Orphenadrine Paroxetine Peginterferon- $\alpha$ 2a Peginterferon- $\alpha$ 2b Pentoxifylline Perphenazine Primaquine	Propafenone Propofol Propranolol Ranitidine Rofecoxib Ropinirole Selegiline Sertraline Sildenafil Sulconazole Tacrine Tenofovir Theophylline Thiabendazole Thioridazine Ticlopidine Ticloconazole Tocainide Tranylcypromine Verapamil Zafirlukast Zileuton
--	---	--	---

### CYP1A2 Inducers

Aminoglutethimide Carbamazepine	Phenobarbital	Primidone	Rifampin
------------------------------------	---------------	-----------	----------

When drugs classified as 'substrates' are co-administered with (*Study Agent*), there is the potential for higher concentrations of the 'substrate'. When (*Study Agent*) is co-administered with compounds classified as 'inhibitors', increased plasma concentrations of (*Study Agent*) is the potential outcome. The co-administration of 'inducers' would potentially lower plasma (*Study Agent*) concentrations.

Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 15<sup>TH</sup> ed. Hudson, OH; LexiComp Inc. 2007: 1899-1912.

Only major substrates and effective inducers are listed.

Additional information for drug interactions with cytochrome P450 isoenzymes can be found at <http://medicine.tupui.edu/flockhart/>.

- (1) Gorski, et al. (2004). *Clin Pharmacol Ther.* 75:89-100.
- (2) Saruwatari, et al. (2003). *J Pharm Pharmacol.* 55:1553-1559.

Updated on May 1, 2007